natgillin/translations-raw huggingface dataset:
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption should not take this medicinal product.
Bolesnici s rijetkim nasljednim problemima nepodnošenja galaktoze, nedostatkom Lapp laktaze ili malapsorpcijom glukoze i galaktoze ne smiju uzimati ovaj lijek.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption should not take this medicinal product.
Pacijenti s rijetkim nasljednim poremećajima nepodnošenja galaktoze, nedostatka Lapp laktaze ili malapsorpcije glukoze-galaktoze ne smiju uzimati ovaj lijek.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactose deficiency or glucose-galactose malabsorption should not take this medicinal product.
Bolesnici s rijetkim nasljednim problemima nepodnošenja galaktoze, nedostatka Lapp laktaze ili malapsorpcije glukoze-galaktoze ne bi trebali uzimati ovaj lijek.
Patients with rare heriditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Bolesnici s rijetkim nasljednim problemima nepodnošenja galaktoze, nedostatka Lapp laktaze ili malapsorpcije glukoze i galaktoze ne bi trebali uzimati ovaj lijek.
Patients with recent acute coronary syndrome a)
Bolesnici s nedavnim akutnim koronarnim sindromom a)
Patients with recent acute coronary syndrome undergoing PCI a)
Bolesnici s nedavnim akutnim koronarnim sindromom bolesnika koji su podvrgnuti perkutanom koronarnom zahvatu a)
Patients with recurrent or progressive malignant glioma
Bolesnici s recidivirajućim ili progresivnim malignim gliomom:
Patients with reduced haematologic reserve have not been studied in clinical trials.
Bolesnici sa smanjenim rezervama koštane srži nisu uključivani u klinička ispitivanja.
patients with reduced liver function;
bolesnika sa smanjenom funkcijom jetre
patients with reduced liver function;
bolesnika sa smanjenom funkcijom jetre;
Patients with refractory asthmad
Bolesnici s refrakternom astmomd
Patients with relapsing remitting multiple sclerosis and two or more relapses within the last two years.
Bolesnika s relapsno remitirajućom multiplom sklerozom koji su doživjeli dva ili više relapsa unutar posljednje dvije godine.
Patients with relapsing-remitting MS have periods when the disease is not active (remission) in between flare-ups of symptoms (relapses).
Bolesnici s relapsnom remitirajućom MS-om imaju razdoblja kada bolest nije aktivna (remisija) između razdoblja kada simptomi pogoršaju (relapsi).
patients with relapsing-remitting multiple sclerosis and two or more relapses within the last two years. patients with secondary progressive multiple sclerosis with active disease, evidenced by relapses.
bolesnika s relapsno-remitirajućom multiplom sklerozom koji su doživjeli dva ili više relapsa unutar posljednje dvije godine. bolesnika sa sekundarno progresivnom multiplom sklerozom s aktivnom bolešću što se dokazuje relapsima.
Patients with renal and hepatic impairments should be closely monitored.
Bolesnike s oštećenjima funkcije jetre i bubrega mora se pažljivo pratiti.
Patients with renal and/or hepatic impairment
Bolesnici s oštećenjem bubrega i/ili jetre
Patients with renal and/or hepatic impairment should be monitored more closely. (see section 4.4)
Pacijente s bubrežnim i/ili jetrenim oštećenjem potrebno je pažljivije pratiti (vidjeti dio 4.4).
Patients with renal and/or hepatic impairment:
Bolesnici s oštećenjem bubrega i/ili jetre:
Patients with renal angiomyolipoma associated with TSC:
Bolesnici s bubrežnim angiomiolipomom povezanim s KTS-om:
Patients with renal disease
Bolesnici s bolešću bubrega
Patients with renal impairement (see section 5.2)
Bolesnici s oštećenjem bubrega (vidjeti dio 5.2)
Patients with renal impairment
Bolesnice s oštećenjem bubrega
Patients with renal impairment
Bolesnice s oštećenjem funkcije bubrega
Patients with renal impairment
Bolesnici s oštećenjem bubrega)
Patients with renal impairment
Osobe s oštećenjem funkcije bubrega
Patients with renal impairment
Pacijenti s oštećenjem bubrega
Patients with renal impairment
Pacijenti s oštećenjem funkcije bubrega
Patients with renal impairment (see section 4.2, 4.4, and 5.2)
Bolesnici s oštećenjem bubrežne funkcije (vidjeti dijelove 4.2, 4.4, i 5.2)
Patients with renal impairment (see sections 4.2, 4.3, 4.4, and 5.2)
Bolesnici sa oštećenjem bubrega (vidjeti dijelove 4.2, 4.3, 4.4 i 5.2)
Patients with renal impairment (Standard Cockcroft and Gault formula or glomerular filtration rate measured Tc99m DPTA serum clearance method)
Bolesnici s oštećenjem bubrega: (serumski klirens izračunat standardnom Cockcroftovom i Gaultovom formulom ili metodom mjerenja stope glomerularne filtracije Tc99m-DPTA)
Patients with renal impairment (Standard Cockcroft and Gault formula or Glomerular Filtration Rate measured Tc99m-DPTA serum clearance method)
Bolesnici s oštećenjem funkcije bubrega (Serumski klirens izračunat standardnom Cockcroftovom i Gaultovom formulom ili metodom mjerenja brzine glomerularne filtracije Tc99m-DPTA).
Patients with renal impairment (Standard Cockcroft and Gault formula or Glomerular Filtration Rate measured Tc99m-DPTA serum clearance method): Pemetrexed is primarily eliminated unchanged by renal excretion.
Bolesnici s oštećenjem bubrega: (serumski klirens izračunat standardnom Cockcroftovom i Gaultovom formulom ili metodom mjerenja brzine glomerularne filtracije Tc99m-DPTA): Pemetreksed se prvenstveno eliminira putem bubrega u nepromijenjenom obliku.
Patients with renal impairment and/or hyperkalaemia
Bolesnici s oštećenjem funkcije bubrega i/ili hiperkalijemijom
Patients with renal impairment of a higher severity grade than mild have not been investigated.
U ispitivanja nisu uključivani bolesnici s oštećenjem funkcije bubrega većeg stupnja od blagog.
Patients with renal impairment.
Bolesnici s oštećenjem bubrežne funkcije.
Patients with renal impairment:
Bolesnici s oštećenjem bubrega:
Patients with renal impairment:
Bolesnici s oštećenjem funkcije bubrega:
Patients with renal impairment:
Osobe s oštećenjem bubrega:
Patients with renal impairment: (Standard Cockcroft and Gault formula or Glomerular Filtration Rate measured Tc99m-DPTA serum clearance method): Pemetrexed is primarily eliminated unchanged by renal excretion.
Bolesnici s oštećenjem bubrega: (serumski klirens izračunat standardnom Cockcroftovom i Gaultovom formulom ili metodom mjerenja brzine glomerularne filtracije Tc99m-DPTA): Pemetreksed se prvenstveno eliminira putem bubrega u nepromijenjenom obliku.
Patients with renal impairment: No change in dose is required for renal impairment.
Bolesnici s oštećenjem bubrega: Kod oštećenja bubrega nije potrebna promjena doze.
Patients with renal impairment: Rasagiline's pharmacokinetics characteristics in subjects with mild (CLcr 50-80 ml/min) and moderate (CLcr 30-49 ml/min) renal impairment were similar to healthy subjects.
Bolesnici s oštećenjem bubrega: Karakteristike farmakokinetike razagilina u osoba s blagim (CLcr 50-80 ml/min) i umjerenim (CLcr 30-49 ml/min) oštećenjem bubrega su slične onima zdravih osoba.
Patients with renal impairment: Renal impairment does not affect the pharmacokinetics of entacapone.
Bolesnici s oštećenjem bubrega: oštećenje bubrega ne utječe na farmakokinetiku entakapona.
Patients with renal impairment: Renal impairment does not affect the pharmacokinetics of entacapone.
Bolesnici s oštećenjem: oštećenje bubrega ne utječe na farmakokinetiku entakapona.
Patients with renal impairment: Since tenofovir disoproxil fumarate can cause renal toxicity, close monitoring of renal function is recommended in any patient with mild renal impairment treated with Atripla (see sections 4.2, 4.4 and 5.2).
Pacijenti s oštećenjem funkcije bubrega: Tenofovirdizoproksil fumarat može prouzročiti bubrežnu toksičnost pa se preporučuje pomno nadziranje funkcije bubrega u svakog pacijenta s blagim oštećenjem funkcije bubrega koji se liječi Atriplom (vidjeti dio 4.2, 4.4 i 5.2).
Patients with renal impairment: The dose for patients with severe renal impairment (GFR < 30 ml/min/1.73 m2) is 1 mg once daily (see sections 4.3 and 5.2).
Bolesnici s oštećenjem funkcije bubrega: Za bolesnike s teškim oštećenjem funkcije bubrega (GFR < 30 ml/min/1,73 m2) doza je 1 mg jedanput na dan (vidjeti dijelove 4.3 i 5.2).
Patients with renal impairment: The safety and efficacy have not been studied in patients with renal impairment (see section 5.2).
Bolesnici s oštećenjem bubrežne funkcije: Nisu ispitivane sigurnost primjene i djelotvornost u bolesnika s oštećenjem bubrežne funkcije (vidjeti dio 5.2).
Patients with renal impairment: The safety and efficacy of erlotinib has not been studied in patients with renal impairment (serum creatinine concentration >1.5 times the upper normal limit).
Bolesnici s oštećenjem bubrega: Sigurnost i djelotvornost erlotiniba nije ispitana u bolesnika s oštećenjem bubrega (koncentracija serumskog kreatinina > 1,5 puta od gornje granice normale).
Patients with renal insufficiency can also be managed by administration of Emtriva 10 mg/ml oral solution to provide a reduced daily dose of emtricitabine.
Pacijenti s insuficijencijom bubrega mogu se liječiti i primjenom Emtriva 10 mg/ml oralne otopine da bi se smanjila dnevna doza emtricitabina.
Patients with renal insufficiency can also be managed by administration of Emtriva 200 mg hard capsules at modified dose intervals.
Pacijenti s insuficijencijom bubrega mogu se liječiti i primjenom Emtriva 200 mg tvrdih kapsula uz prilagoĎene intervale doziranja.
Patients with renal insufficiency may develop hypocalcaemia or hypercalcaemia.
Bolesnici s bubrežnom insuficijencijom mogu razviti hipokalcemiju ili hiperkalcemiju.
Patients with renal insufficiency requiring dialysis have not been studied in clinical trials.
Nisu provedena klinička ispitivanja u bolesnika s bubrežnom insuficijencijom koji se liječe dijalizom.
patients with renal or hepatic
Bolesnici koji počinju ili prestaju
Patients with renal or hepatic impairment
Bolesnice s oštećenjem bubrežne ili jetrene funkcije
Patients with renal or hepatic impairment
Bolesnice s oštećenjima bubrega ili jetre
Patients with renal or hepatic impairment
Bolesnici s oslabljenom funkcijom bubrega ili jetre
Patients with renal or hepatic impairment
Bolesnici s oštećenjem funkcije bubrega i jetre
Patients with renal or hepatic impairment should be monitored closely.
Potrebno je pažljivo pratiti bolesnike s oštećenjem funkcije bubrega ili jetre.
Patients with Resistance Mutations (%)
Bolesnici s otpornim sojevima (%)
Patients with restrictive or congestive cardiomyopathy
bolesnici s restriktivnom ili kongestivnom kardiomiopatijom
Patients with rheumatoid arthritis, GPA or MPA must not receive MabThera if they have severe heart problems.
Bolesnici s reumatoidnim artritisom i bolestima GPA ili MPA ne smiju primati lijek MabThera ako imaju ozbiljne probleme sa srcem.
Patients with risk factors should be closely monitored for respiratory symptoms before and during ONIVYDE therapy.
Bolesnike s čimbenicima rizika potrebno je pomno pratiti radi respiratornih simptoma prije i tijekom liječenja lijekom ONIVYDE.
Patients with RRMS, with at least 2 relapses within the prior 3 years, and 1 relapse in the prior year, with an EDSS score of ≤5.0
Bolesnici s RRMS-om, s najmanje 2 relapsa prethodne 3 godine, i 1 relapsom u prethodnoj godini s EDSS ocjenom ≤ 5,0
Patients with RRMS, with at least 2 relapses within the prior 3 years, and 1 relapse in the prior year, with an EDSS score of ≤5.0
Bolesnici s RRMS-om, s najmanje 2 relapsa u prethodne 3 godine, i 1 relapsom u prethodnoj godini s EDSS ocjenom ≤ 5,0
Patients with secondary progressive multiple sclerosis with active disease, evidenced by relapses.
Bolesnika sa sekundarno progresivnom multiplom sklerozom s aktivnom bolešću što se dokazuje relapsima.
Patients with SEGA associated with TSC: Patients <18 years of age:
Bolesnici sa SEGA-om povezanom s KTS-om: Bolesnici mlađi od 18 godina:
Patients with seizures and signs/symptoms consistent with RPLS, such as hypertension, headache, decreased alertness, altered mental functioning and visual loss, including cortical blindness, should be controlled with medical management including control of hypertension.
Bolesnike s napadajima te znakovima/ simptomima koji upućuju na RPLS, kao što su hipertenzija, glavobolja, smanjena budnost, promjene mentalnih funkcija te gubitak vida koji obuhvaća i kortikalnu sljepoću, treba kontrolirati i liječiti, uključujući i kontrolu hipertenzije.
Patients with serious infections (see section 4.4),
Bolesnici s ozbiljnim infekcijama (vidjeti dio 4.4.)
Patients with serious infections (see section 4.4).
Bolesnici s ozbiljnim infekcijama (vidjeti dio 4.4).
Patients with serious infections (see section 4.4).
Bolesnici s ozbiljnim infekcijama (vidjeti dio 4.4.)
Patients with serious infections (see section 4.4).
Bolesnici s ozbiljnim infekcijama (vidjeti dio 4.4.).
Patients with serious infections should not start treatment with Tecfidera until the infection(s) is resolved.
Bolesnici s ozbiljnim infekcijama ne smiju započeti liječenje Tecfiderom sve dok infekcija(e) nije riješena.
Patients with serum creatinine > 1.5 x Upper Limit of the Normal range (ULN) were excluded from the randomised study.
Bolesnici s razinom serumskog kreatinina > 1,5 x iznad gornje granice referentnih vrijednosti isključeni su iz ispitivanja metodom slučajnog odabira.
Patients with serum creatinine > 1.5×ULN were excluded from the CML studies.
Bolesnici sa serumskim kreatininom >1,5 × GGN bili su isključeni iz ispitivanja KML-a.
Patients with serum creatinine >1.5×ULN were excluded from CML studies.
Bolesnici sa serumskim kreatininom >1,5 × GGN bili su isključeni iz ispitivanja KML-a.
Patients with serum total bilirubin > 2.0 mg/dL were excluded from clinical studies.
Bolesnici s ukupnim bilirubinom u serumu >2,0 mg/dl bili su isključeni iz kliničkih ispitivanja.
Patients with severe aortic stenosis, patients with systolic blood pressure < 100 mm Hg, and patients with heart failure class NYHA III and NYHA IV.
Bolesnici s teškom stenozom aorte, bolesnici čiji je sistolički krvni tlak < 100 mm Hg i bolesnici sa zatajenjem srca stupnja III i IV prema NYHA klasifikaciji.
Patients with severe asthma and COPD were shown to be able to generate sufficient inspiratory flow rate when they breathed in forcefully through the Spiromax device to enable the delivery of the required therapeutic dose to the lungs (see also section 5.1 – last five paragraphs)
Bolesnici s teškom astmom i KOPB-om, kada snažno udahnu kroz Spiromax inhalator,.mogu stvoriti dovoljnu brzinu protoka zraka tijekom udaha da bi se iz Spiromaxa isporučila terapijska doza u pluća (također vidjeti dio 5.1 – zadnjih 5 odlomaka)
Patients with severe asthma may rarely present systemic hypereosinophilic syndrome or allergic eosinophilic granulomatous vasculitis (Churg-Strauss syndrome), both of which are usually treated with systemic corticosteroids.
Bolesnici s teškom astmom mogu rijetko oboljeti od sistemskog hipereozinofilnog sindroma ili alergijskog eozinofilnog granulomatoznog vaskulitisa (Churg-Straussov sindrom), a oba se uglavnom liječe sistemskim kortikosteroidima.
Patients with severe bone marrow failure should not be treated with ONIVYDE.
Bolesnici s teškim zatajenjem koštane srži ne smiju se liječiti lijekom ONIVYDE.
Patients with severe cardiovascular disease were excluded from IMBRUVICA clinical studies.
Bolesnici s teškom kardiovaskularnom bolesti nisu bili uključeni u klinička ispitivanja lijeka IMBRUVICA.
Patients with severe hepatic cirrhosis (Child-Pugh Class C) have not been studied and therefore dosing of tadalafil in these patients is not recommended .
Bolesnici s teškom cirozom jetre (Child-Pugh stadij C) nisu ispitivani te se stoga u tih bolesnika primjena tadalafila ne preporučuje.
Patients with severe hepatic impairment (Child-Pugh C) have not been studied (see section 5.3).
Bolesnici s teškim oštećenjem jetre (Child-Pugh stadij C) nisu ispitivani (vidjeti dio 5.3).
Patients with severe hepatic impairment (Child-Pugh C) or pre-treatment ASAT or ALAT > 5 ULN until baseline ASAT/ALAT are stabilised < 5 ULN
Bolesnici s teškim oštećenjem jetre (Child-Pugh C) ili osobe koje su u fazi prije liječenja imali AST ili ALT > 5 x gornja granica normale (GGN) sve dok se vrijednosti AST/ALT ne stabiliziraju na razini < 5 x GGN.
Patients with severe hepatic impairment (see sections 4.2 and 5.2)
Bolesnici s teškim oštećenjem jetre (vidjeti dijelove 4.2 i 5.2).
Patients with severe hepatic impairment (with or without cirrhosis) (see section 4.2).
Bolesnici s teškim oštećenjem jetre (s cirozom ili bez nje) (vidjeti dio 4.2).
Patients with severe hepatic impairment have not been studied, however, rivastigmine oral solution may be used in this patient population provided close monitoring is exercised (see sections 4.4 and 5.2).
Nisu proučavani bolesnici s teškim oštećenjem jetre, no oralna otopina rivastigmina može se koristiti u ovoj populaciji bolesnika uz pažljivo praćenje (vidjeti dijelove 4.4 i 5.2).
Patients with severe hepatic impairment have not been studied.
Bolesnici s teškim oštećenjem jetre nisu bili ispitivani.
Patients with severe hepatic impairment have not been studied.
Nisu proučavani bolesnici s teškim oštećenjem jetre.
Patients with severe hypoproteinaemia, e.g. in nephrotic syndrome,
Bolesnici s teškom hipoproteinemijom, npr. kod nefrotskog sindroma
Patients with severe hypoproteinaemia, e.g. in nephrotic syndrome.
Bolesnici s teškom hipoproteinemijom, npr. kod nefrotskog sindroma
Patients with severe hypoproteinaemia, e.g. in nephrotic syndrome.
Bolesnici s teškom hipoproteinemijom, npr. kod nefrotskog sindroma.
Patients with severe immunodeficiency states, e.g.
Bolesnici s teškim imunodeficijentnim stanjima, npr.
Patients with severe immunodeficiency states, e.g.
Bolesnici s teškim stanjima imunodeficijencije, npr.
Patients with severe kidney disease cannot eliminate phosphate from their bodies.
Bolesnici s ozbiljnom bolešću bubrega ne mogu eliminirati fosfat iz svojih tijela.
Patients with severe lactose intolerance should use this medicine with caution and those with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Bolesnici s teškom intolerancijom laktoze trebaju koristiti ovaj lijek s oprezom, a bolesnici s rijetkim nasljednim poremećajem intolerancije galaktoze, nedostatkom Lapp laktaze ili malapsorpcijom glukoze i galaktoze ne bi trebali uzimati ovaj lijek.
patients with severe leucopenia, neutropenia, or thrombocytopenia (low levels of white cells or platelets in the blood);
u bolesnika s ozbiljnom leukopenijom, neutropenijom ili trombocitopenijom (niskim razinama bijelih stanica ili trombocita u krvi);
patients with severe liver disease or end-stage kidney disease requiring dialysis;
bolesnici s teškom bolesti jetre ili terminalnom bolesti bubrega koji trebaju dijalizu;
Patients with severe liver impairment (see sections 4.2 and 4.4).
Bolesnici s teškim oštećenjem funkcije jetre (vidjeti dio 4.2. i 4.4).
Patients with severe liver impairment (see sections 4.2 and 4.4).
Bolesnici s teškim oštećenjem jetre(vidjeti dijelove 4.2. i 4.4).
Patients with severe liver impairment (see sections 4.2 and 4.4).
Docetaksel se ne smije primjenjivati u bolesnika s teškim oštećenjima jetre (vidjeti dio 4.2. i 4.4).
patients with severe liver or kidney disease; patients treated with sorivudine or similar cancer medicines such as brivudine within the last four weeks.
u bolesnika s ozbiljnim bolestima jetre ili bubrega; u bolesnika liječenih sorivudinom ili sličnim antikancerigenim lijekovima, kao što je brivudin unutar razdoblja od posljednja četiri tjedna.
Patients with severe lung problems or with smoker’s cough may have a higher chance of developing side effects.
Kod bolesnika koji imaju teške plućne probleme ili pušački kašalj mogla bi postojati veća vjerojatnost za razvoj nuspojava.
Patients with severe neutropenia (absolute neutrophil count < 1 X 109/L) should discontinue INVEGA and have their WBC followed until recovery.
Bolesnici s teškom neutropenijom (apsolutni broj neutrofila < 1 X 109/l) trebaju prestati uzimati INVEGU, te im je potrebno pratiti leukocite pratiti do opravka.
Patients with severe neutropenia (absolute neutrophil count < 1 X 109/L) should discontinue Xeplion and have their WBC followed until recovery.
Bolesnici s teškom neutropenijom (apsolutni broj neutrofila < 1 X 109/l) trebaju prestati uzimati Xeplion, te im je potrebno pratiti leukocite pratiti do oporavka.
Patients with severe peripheral circulatory disturbance/disorders (i.e. severe forms of Raynaud’s disease or Raynaud’s syndrome) should be treated with caution.
Bolesnike s teškim perifernim cirkulacijskim bolestima/poremećajima (npr. teški oblici Raynaudove bolesti ili Raynaudovog sindroma) treba liječiti s oprezom.
Patients with severe peripheral circulatory disturbance/disorders (i.e. severe forms of Raynaud’s disease or Raynaud’s syndrome) should be treated with caution.
Bolesnike s teškim poremećajima/bolestima periferne cirkulacije (npr. teški oblici Raynaudove bolesti ili Raynaudova sindroma) mora se liječiti s oprezom.
Patients with severe peripheral circulatory disturbance/disorders (i.e. severe forms of Raynaud’s disease or Raynaud’s syndrome) should be treated with caution.
Bolesnike sa teškim perifernim cirkulacijskim poremećajima/bolestima (npr. teški oblici Raynaudove bolesti ili Raynaudova sindroma) se mora liječiti s oprezom.
Patients with severe persistent asthma, chronic obstructive pulmonary disease (COPD), or are heavy smokers may be at increased risk for cancer with Simponi treatment.
Bolesnici s teškom trajnom astmom, kroničnom opstruktivnom bolešću pluća (KOPB) i teški pušači mogu imati povećan rizik za nastanak raka tijekom liječenja lijekom Simponi.
Patients with severe refractory eosinophilic asthma
Bolesnici s teškom refraktornom eozinofilnom astmom
Patients with severe renal disease will accumulate the inactive acetyl metabolite of para-aminosalicylic acid.
Bolesnici s teškom bolesti bubrega akumuliraju neaktivan acetil metabolit paraaminosalicilatne kiseline.
Patients with severe renal impairement (creatinine clearance <30 ml/min) should be treated with caution.
Bolesnike s teškim oštećenjem bubrega (klirens kreatinina <30 ml/min) treba liječiti s oprezom.
Patients with severe renal impairment (CrCL < 30 mL/min) (see section 4.2)
Bolesnici s teškim oštećenjem bubrega (CrCl < 30 mL/min) (vidjeti dio 4.2)
Patients with severe renal impairment (creatinine clearance < 30 ml/min) or receiving dialysis are at greater risk of developing hypocalcaemia.
Bolesnici s teškim oštećenjem bubrega (klirens kreatinina < 30 ml/min) ili bolesnici koji su na dijalizi imaju povećan rizik za razvoj hipokalcijemije.
Patients with severe renal impairment (creatinine clearance < 30 ml/min) or receiving dialysis are at greater risk of developing hypocalcaemia.
Bolesnici s teškim oštećenjem funkcije bubrega (klirens kreatinina < 30 ml/min) ili bolesnici koji su na dijalizi imaju povećan rizik za razvoj hipokalcijemije.
Patients with severe renal impairment (defined as eGFR < 30 mL/min/1.73 m2) have not been studied (see section 5.3).
Bolesnici s teškim oštećenjem bubrega (definiranim kao eGFR < 30 ml/min /1,73 m2) nisu ispitivani (vidjeti dio 5.3).
Patients with severe renal impairment (eGFR <30 ml/min per 1.73 m2).
Bolesnici s teškim oštećenjem bubrega (eGFR <30 ml/min na 1,73 m2).
Patients with severe renal impairment have not been studied.
Bolesnici s teškim oštećenjem funkcije bubrega nisu ispitivani.
Patients with severe renal impairment receiving Eperzan experienced a higher frequency of diarrhoea, nausea, and vomiting compared to patients with mild or moderate renal impairment.
U bolesnika s teškim oštećenjem bubrežne funkcije liječenih lijekom Eperzan zabilježena je povećana učestalost proljeva, mučnine i povraćanja u usporedbi s bolesnicima s blagim ili umjerenim oštećenjem bubrežne funkcije.
Patients with severe renal impairment should not receive GRANUPAS.
Bolesnici s teškim oštećenjem funkcije bubrega ne smiju primati GRANUPAS.
Patients with severe renal impairment.
Pacijentice s teškim oštećenjem bubrega.